

# **Efficacy of Heart Failure Reversal Therapy (HFRT) in Post-menopausal Female Patients with Preserved Ejection Fraction (>40%)**

**Rohit Sane<sup>1</sup> and Rahul Mandole<sup>1\*</sup>**

<sup>1</sup>Department of Research and Development, Madhavbaug Cardiac Care Clinics and Hospital, Mumbai, Maharashtra, India.

### **Authors' contributions**

*This work was carried out in collaboration between both authors. Author RS designed the study and author RM performed the statistical analysis, wrote the protocol, wrote the first draft of the manuscript, managed the analyses of the study and managed the literature searches. Both authors read and approved the final manuscript.*

### **Article Information**

DOI: 10.9734/AJCR/2019/43550

#### Editor(s):

(1) Dr. Hugo R. Ramos, Adjunct Professor, Department of Internal Medicine, Hospital de Urgencias, Córdoba, Argentina.

(2) Dr. Sam Said, Department of Cardiology, Hospital Group Twente, Hengelo, The Netherlands.

#### Reviewers:

(1) Paul Schoenhagen, USA.

(2) Arthur N. Chuemere, University of Port Harcourt, Nigeria.

(3) Ramachandran Muthiah, Thoothukudi Medical College Hospital, India.

(4) Aşkın Ender Topal, Dicle University, Turkey.

Complete Peer review History: <http://www.sdiarticle3.com/review-history/43550>

**Original Research Article**

**Received 26 July 2018**

**Accepted 16 October 2018**

**Published 31 January 2019**

## **ABSTRACT**

**Purpose:** Mortality in women around the world is attributed majorly to CVDs. Around 4.5 Lac women die annually due to plethora of CVDs like Heart Failure (HF) and Ischemic Heart Disease or their complications. Especially, postmenopausal women are majorly affected by CVDs. This study was conducted to evaluate the effect of Heart Failure Reversal Therapy (HFRT) on VO<sub>2</sub>max, Blood Pressure (BP), Body Mass Index (BMI), abdominal Girth and Heart Rate.

**Methods:** This observational study was conducted from January 2015 to December 2017, wherein the data of post-menopausal CHF patients (New York Heart Association, NYHA Class I–II) with preserved ejection fraction, who attended out-patient departments (OPDs) at *Madhavbaug Hospital in Khopoli, Maharashtra, India* were identified. Data of patients who were administered HFRT (60–75 minutes) with minimum 7 sittings over 7 days were considered. Variables were compared between day 1, 7, 30, 60, and day 90 of HFRT.

**Results:** 71 postmenopausal women were finally enrolled in the study. HFRT showed significant improvement in VO<sub>2</sub>max from 16.53±4.86 to 24.8±6.25, p<0.001. SBP reduced significantly from 124.03±17.02 to 120.76±12.62 (p=0.56) at the end of 90<sup>th</sup> day. Heart rate reduced from 85.79±15.12 to 79.58±10.19 (p< 0.001).

**Conclusion:** HFRT can serve as potent and viable therapeutic option for management of HF in Post-menopausal women with Preserved Ejection Fraction.

**Keywords:** Heart failure reversal therapy; HFRT; panchakarma; heart failure; VO<sub>2</sub>max; menopause; BMI; BP.

## 1. INTRODUCTION

The prevalence of cardiovascular diseases (CVDs) is escalating on alarming scales on global geography. CVDs like heart failure (HF) and ischemic heart disease contribute to maximum deaths in women around the globe, accounting to nearly 4.5 lac deaths annually [1]. Especially, postmenopausal women are majorly affected by CVDs. Lack of oestrogen due to menopause has been shown to be associated with increased cardiovascular morbidity and mortality [2,3]. Due to the protective effects of oestrogen on cardiovascular function like release of endothelial nitric oxide causing arterial vasodilation and reduction in afterload of heart and metabolism, menopause has been considered as major risk factor for CVDs. The interplay of variety metabolic changes due to menopause induced oestrogen withdrawal like decreased glucose tolerance, abnormal plasma lipid levels, increased sympathetic tone, vascular inflammation, endothelial dysfunction, abnormality in fat distribution in the body, contribute to increasing in cardiovascular risk [4].

Despite the availability of extensively laid guidelines for treatment of HF, which suggest the use of pharmacological drugs like vasodilators, beta blockers, angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARBs), in hospital mortality attributed to HF lies in the range of 30%, which is worrisome [5]. Optimal treatment of any disease is vastly dependent on patient adherence to treatment. This has been found to be only 30-50% in Indian HF patients, thus the suboptimal outcome of treatment, resulting in increased morbidity and mortality. Thus, it is dire need of the hour to explore novel therapeutic option which will have multifaceted actions of decreasing cardiovascular morbidity and mortality along with increasing the quality of life by reducing dread and apprehension associated with the diagnosis of disease.

Due to the interplay of several components like concurrent numerous medications, old age, reduction in hepatic and renal function with advancing age, other co-existing diseases, etc.; the treatment of HF is intricate [6]. Major conventional drugs used in the treatment of HF have beneficial effects through their anti-inflammatory and antioxidant actions [7,8]. Similar properties have been found in various herbal drugs in clinical studies, which makes them potent and viable nominees for treatment in patients of HF [9,10,11,12]. Ayurvedic practice of medicine idealizes the concept of administering *Panchakarma* i.e. 4-step internal body purification in chronic phase of the disease, in addition to conventional drugs used in acute phase of disease [13]. A combination of *Panchakarma* and diet therapy is given under the span of Heart Failure Reversal Therapy (HFRT) [14]. Four detoxifying techniques are used in *Panchakarma* of HFRT- *Snehana* (Oleation therapy), *Swedana* (Passive heat treatment), *Hrudaydhara* (Concoction dripping therapy) and *Basti* (Per rectal drug administration) [13,15].

Routine work capacity/exercise tolerance is drastically reduced in patients of HF, which is measured currently by VO<sub>2</sub>max, also known as maximum aerobic capacity/maximum exercise capacity [16]. Since this adversely affects the performance of daily usual work, quality of life is also drastically reduced [17,18]. Hence, we planned an observational study with the objective of assessing the effect of HFRT in postmenopausal patients of HF with preserved ejection fraction. We also assessed the effect of HFRT on weight, body mass index (BMI), abdominal girth, systolic blood pressure (SBP), diastolic BP (DBP).

## 2. MATERIALS AND METHODS

This was an observational study conducted between January 2015 to December 2017, wherein we identified the data of postmenopausal patients suffering from CHF (New

York Heart Association, NYHA Class (I-II) with preserved ejection fraction (EF>40%), who had attended the out-patient departments (OPDs) at *Madhavbaug Hospital in Khopoli, Maharashtra, India.*

HFRT was administered twice daily for consecutive 7 days to CHF patients. Cases were identified, and data were assessed from the records of *Madhavbaug clinics in Khopoli, Maharashtra, India.*

The selection was based upon the availability of complete relevant baseline data (day 1 of HFRT) and final day data (day 90 of HFRT) of the patients. The information about prescribed concomitant medicines or comorbidities, if any, was also noted down.

The HFRT is a 4-step procedure which was performed on the patients with CHF after a light breakfast. One sitting of the procedure took 65-75 minutes, as described in Table 1 [13,15].

## 2.1 Follow-up Flow is Given as Follows

On day 1, the patients physical examinations (VO<sub>2</sub>max, SBP, DBP, weight, BMI and Abdominal Girth), 2D Echo (Ejection Fraction) were performed. Then, 2 *Panchakarma* therapy (morning and evening) is given to the patients. This pattern is followed for the next 7 days during the hospitalisation with a diet plan of 1000-1200 kcals per day.

Then again on 7th day same tests were repeated. After discharge, the patients are called for follow-up, i.e. 30-days, 60-days and 90-days after 7 days of HFRT. Same Test were performed in every follow up. One way ANOVA (Table 2) was used to test statistical significance for Primary endpoint (Improvement in VO<sub>2</sub>max) and secondary endpoint (Reduction in Weight, BMI, abdominal Girth, Heart Rate, SBP and DBP) for a washout period (DoA, DoD, 1st follow up, 2<sup>nd</sup> Follow up and 3<sup>rd</sup> Follow up). We used R (Version 3.5.0) software and excel to analyze the data.

**Table 1. Study treatment: Heart failure reversal therapy (HFRT)**

Step of HFRT	Type of Therapy	Herbs used for therapy	Duration of Therapy
<i>Snehana</i>	Massage or external oleation (centripetal upper strokes directed towards heart)	10 grams <i>T. arjuna</i> , 10 grams <i>Dashamoola</i> and 5 grams <i>V.negundo</i> [100 ml extract processed in <i>sesame oil</i> ]	30-35 minutes
<i>Swedana</i>	Passive heat therapy	<i>Dashmoola</i> (group of ten herbal roots) with steam at $\leq 40$ degrees Celsius)	10-15 minutes + 34 minutes of relaxation after procedure
<i>Hrudaydhara</i>	Decoction dripping therapy from a height of 7-8 cm	Luke-warm <i>dashmoola</i> decoction	15 minutes
<i>Basti</i>	Drug administered per rectal, should be in body for $\geq 15$ minutes for maximum absorption	1.88 grams <i>T. arjuna</i> , 0.42 grams <i>B. diffusa</i> and 0.18 grams <i>A. calamus</i> [10 ml aqueous extract]	10 minutes

**Table 2. Hypothesis for ANOVA test**

Null Hypothesis	Means are equal among all 5 different time periods i.e. DOA, DOD, 1 f/u, 2 f/u & 3 f/u
Alternative Hypothesis	Means of at least 2 groups are significantly different
Level of significance	0.05

### 3. RESULTS

#### 3.1 Study Population

A total of 100 patients' data was screened for inclusion in the study. However, based on the availability of data (Day 1, 7, 30, 60 and day 90) and the inclusion criteria, 71 patients were selected, and their data were considered for analysis (Fig. 1). The baseline characteristics of these patients are shown in Table 3.

HFRT program in post-menopausal female patients with preserved EF, there were 71 cases and baseline data included age, height, LV, EF, past medical history and NYHA Functional class variables. These baseline findings are depicted in Table 3.

The baseline characteristics of the study populations are shown in Table 3. In that 71 subjects, 22 (30.99%) had Coronary artery disease (CAD), 56 (78.87%) had Hypertension (HTN), 33 (46.48%) had Diabetic Mellitus (DM), 36 (50.7%) had ischemic heart disease (IHD), 14 (19.72%) had Obesity, 14 (19.72%) had Dyslipidemia, 11 (15.49%) had Congestive Heart Failure, 3 (4.23%) had Thyroidism, 2 (2.82%) had PTCA, 5 (7.04%) had Myocardial infarction and 1 (1.41%) had UA.

Effect of HFRT treatment on the improvement of body parameter is summarised in Table 4. For all


71 cases, HFRT treatment showed significant (high statistical significance) improvement in weight, BMI, Abdominal Girth, and VO2 Max, Heart Rate. HFRT treatment was not statistically significant for SBP, DBP.

**Table 3. Baseline characteristics of the study subjects (n= 71)**

Variable	Mean ± SD
Gender (F)	71
Age (Years)	63.65±3.27
Height (cm)	152.54±6.14
EF	58.41±5.65
Past medical history Frequency (%)	
CAD	22 (30.99)
HTN	56 (78.87)
DM	33 (46.48)
ST.IHD	36 (50.7)
OBESITY	14 (19.72)
DYSLIPEDEMIA	14 (19.72)
CHF	11 (15.49)
THYROIDISM	3 (4.23)
PTCA	2 (2.82)
MI	5 (7.04)
UA	1 (1.41)

*Note: - Categorical data were expressed in terms of percentage and continuous data were expressed as Mean ± SD.*


Fig. 2 shows us a comparison of endpoint among all time periods (DoA, DoD, 1st follow up, 2<sup>nd</sup> Follow up and 3<sup>rd</sup> Follow up).



**Fig. 1. Patient enrolment flow chart**

**Table 4. Effect of HFRT treatment on improvement of various body parameters according to overall and NYHA subjects**

Variable	Sample size	Mean ± SD					P-value
		DOA	DOD	1 f/u	2 f/u	3 f/u	
VO2 max	71	16.53±4.86	21.35±5.69	22.96±6.59	24.22±5.98	24.8±6.25	<0.001
Weight	71	62.16±9.93	60.92±9.57	59.78±9.5	58.98±9.11	58.64±8.97	<0.001
BMI	71	26.69±3.87	26.16±3.72	25.67±3.67	25.33±3.5	25.18±3.41	<0.001
Abdominal Girth	71	90.3±9.34	89.01±9.18	87.11±9.84	86.3±9.54	86.55±8.76	<0.001
Heart Rate	71	85.79±15.12	79±11.84	81.25±12.66	78.39±11.47	79.58±10.19	<0.001
SBP	71	124.03±17.02	123.52±12.66	121.18±14.54	121.41±13.55	120.76±12.62	0.56
DBP	71	76.56±9.77	79.3±6.83	77.04±8.18	77.18±8.97	77.32±7.74	0.12



**Fig. 2. Effect of HFRT on clinical parameters**

Thus HFRT treatment was statistically significant for the primary endpoint (Improvement in VO<sub>2</sub>max) but partially significant in case of secondary endpoint (reduction in Weight, BMI, abdominal Girth, Heart Rate). SBP and DBP were statistically insignificant in secondary endpoint.

#### 4. DISCUSSION

Although, wide range of drugs are available for treatment of HF, it still remains one of the leading cause of mortality, especially in postmenopausal patients. Due to these drawbacks of conventional therapy, search for the alternate therapeutic option has gained momentum in recent years. Ayurveda seems to be promising search candidate as an alternative therapeutic option, since many herbal drugs have been shown to possess anti-inflammatory and antioxidant properties which are beneficial in HF similar to traditional allopathic drugs like ACEIs, ARBs, etc. HFRT is administered by Ayurvedic physicians in the treatment of HF as a combination of Panchakarma and diet therapy [19,20]. Keeping these facts in mind, we analysed the effect of HFRT on VO<sub>2</sub>max in post-menopausal patients of HF with preserved EF. VO<sub>2</sub>max was significantly improved consistently till 3<sup>rd</sup> follow up at 90th day after HFRT. BMI, abdominal girth, HR also showed a significant reduction, as compared to baseline, after HFRT.

The possible mechanisms of HFRT might be reduction in HR via anxiolytic effects of Snehana and Hrudaydhara, reduction in sodium and water load by Swedana and reduction in BP by Terminalia arjuna, antioxidant effect of Boerhaavia diffusa due to presence of flavonoid and dihydroxy anisole and anti-inflammatory, antioxidant action of Ascorus calamus; all administered through basti [21,22,23]. Also, HFRT leads to weight loss which might contribute to beneficial cardiovascular effects.

Heart rate is a critical factor in HF patients. Increased heart rate augments the workload on compromised heart i.e. it increases the demand while reducing the supply. Thus, it is very important to control the heart rate in patients of HF. In the present study heart rate increased in 1<sup>st</sup> follow up and then reduced in subsequent follow ups. The initial rise may be due to lack of adherence to low calorie diet and performing strenuous activities.

Cardiorespiratory capacity in an individual is measured by VO<sub>2</sub>max, which in turn is an indicator of work capacity. VO<sub>2</sub>max is reduced in all patients of HF and this reduction is directly proportional to the severity of disease [24]. Significant improvement in VO<sub>2</sub>max in the present study thus signifies better prognosis in patients of HF due to the fact that VO<sub>2</sub>max is directly correlated with functional capacity and secondarily reduced VO<sub>2</sub>max is mortality prognosticator in patients with HF, as is used in majority of clinical trials on CHF to study the efficacy of various interventions. This is corroborated by findings of clinical study done on patients with coronary artery disease, wherein it was found that 15% reduction in mortality was achieved by increasing VO<sub>2</sub>max by 1 ml/kg/min.[25] Thus, better prognosis can be anticipated with HFRT since it led to significant improvement in VO<sub>2</sub>max.

There is limit in exertional capacity in patients with HF, due to which oxygen supply to muscular tissue is reduced. This has been linked to anaerobic formation of lactic acid in the muscle with limited activities. This is reflected in reduced VO<sub>2</sub> max in HF cases. VO<sub>2</sub> max has been accorded as an important prognosticator in HF patients for further risk stratification, identifying heart transplant patients, etc. [26].

Increased mortality is seen in patients of HF with increased BMI, which is marker of obesity.[26] Apart from this, tachycardia/increased heart rate is considered to be major aggravating factor and also a poor prognostic indicator for HF. Therefore, it is commonly seen that each and every guideline on management of HF advocates sustained HR control [27,28,29]. In the present study, there was a significant reduction in HR, which indicates that HFRT may improve prognosis in patients with HF. In order to generalize the findings of our study, it is recommended that similar studies be conducted on large scale with prospective design, more duration of follow up, two arms to allow direct comparison with standard conventional therapy. The limitation of the study was that analysis of weight loss and improvement of VO<sub>2</sub> max was not studied.

#### 5. CONCLUSION

VO<sub>2</sub>max was significantly corrected after treatment with HFRT. Thus, increased VO<sub>2</sub>max coupled with a significant reduction in HR, BMI, abdominal girth after HFRT signifies better

prognosis in post-menopausal patients with HF with preserved ejection fraction >40%.

## CONSENT

We took a consent from all patients that they have no objection over publication of data by keeping confidentiality over their personal details.

## ETHICAL APPROVAL

Yes, we considered the ethics, it's a retrospective data analysis.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Harrison-Bernard L, Raij L. Postmenopausal hypertension. *Curr Hypertens Rep.* 2000;2:202-07.
2. Giardina E. Heart disease in women. *Int J Fertil Womens Med.* 2000;45:350-57.
3. Zárate A, Saucedo R, Basurto L, et al. Cardiovascular disease as a current threat of older women. Relation to estrogens. *Ginecol Obstet Mex.* 2007;75:286-92.
4. Mendelsohn M. Protective effects of estrogen on the cardiovascular system. *Am J Cardiol.* 2002;89(12A):12E-17E. discussion 17E-18E.
5. Rosano G, Vitale C, Marazzi G, et al. Menopause and cardiovascular disease: The evidence. *Climacteric.* 2007;10(1):19-24.
6. Seth S, Ramakrishnan S, Parekh N, et al. Heart failure guidelines for India: Update 2017. *J Pract Cardiovasc Sci.* 2017;3:133-8
7. Quick reference guide for health professionals: Diagnosis and management of chronic heart failure [Internet]. Canberra, Australia: Heart Foundation; 2011. Available:<http://www.heartfoundation.org.au/SiteCollectionDocuments/Chronic-heart-failureQRG-2011.pdf> (Access on 12th April 2018.)
8. Rehsia N, Dhalla N. Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. *Exp Clin Cardiol.* 2010;15:e86–e95.
9. Dandona P, Ghanim H, Brook D. Antioxidant activity of carvedilol in cardiovascular disease. *J Hypertens.* 2007;25:731–41.
10. Gardner C, Lawson L, Block E, et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: A randomized clinical trial. *Arc Intern Med.* 2007;167: 346–53.
11. Kim E, Chen Y, Huang J, et al. Evidence-based toxicity evaluation and scheduling of Chinese herbal medicines. *J Ethnopharmacol.* 2013;146:40–61.
12. Nasa Y, Hashizume H, Hoque A, et al. Protective effect of Crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart. *Arzneimittelforschung.* 1993;43:945-49.
13. Papandreou D, Phily A. An updated mini review on grapefruit: Interactions with drugs, obesity and cardiovascular Risk factors. *Food Nutri Sci.* 2014;5:376–81.
14. Sane R, Aklujkar A, Patil A, et al. Effect of heart failure reversal treatment as add-on therapy in patients with chronic heart failure: A randomized, open-label study. *Indian Heart Journal.* 2017;69(3):299-304.
15. Vinjamury S, Vinjamury M, Sucharitakul S, et al. Panchakarma: Ayurvedic detoxification and allied therapies-is there any evidence? In: Evidence-based practice in complementary and alternative medicine. Berlin, Heidelberg: Springer. 2012;113-137.
16. Uebaba K, Xu F, Ogawa H, et al. Psycho neuro immunologic effects of ayurvedic oil dripping treatment. *J Altern Complement Med.* 2008;14:1189-1198.
17. Ross R, Murthy J, Wollak I, et al. The six minute walk test accurately estimates mean peak oxygen uptake *BMC Pulmonary Medicine.* 2010;31:1-9.
18. Taghadosi M, Arani Z, Gilasi H. Quality of life in patients with ischemic heart disease. *Journal of Nursing and Midwifery Sciences.* 2014;1(1):19-26.
19. Sane R, Hanchate M. Effect of the Sampurna Hridaya Shuddhikaran (SHS) model in heart failure patients in India: A prospective study. *Br J Med Med Res.* 2014;1:564.
20. Arena R, Cahalin L, Borghi-Silva A, et al. Improving functional capacity in heart failure. *Current Opinion in Cardiology.* 2014;29(5):467-74.
21. Liu S. *Terminalia arjuna* Bark and inotropic therapy for heart failure. *International*

- Journal of Genuine Traditional Medicine. 2012;2(3):e21.
22. Mukherjee P, Kumar V, Mal M, et al. *Acorus calamus*. Scientific validation of ayurvedic tradition from natural resources. *Pharmaceutical Biology*. 2007;45:8:651-666.
  23. Khan S, Ansari I, Ahmad S, et al. Chemotherapeutic potential of *Boerhaavia diffusa* Linn: A review. *J App Pharm Sci*. 2013;3(01):133-139.
  24. Piepoli M, Guazzi M, Boriani G, et al. Exercise intolerance in chronic heart failure: Mechanisms and therapies. Part II. *Eur J Cardiovasc Prev Rehabil* 2010;17: 643–648.
  25. Khan H, Kunutsor S, Rauramaa R, et al. Cardiorespiratory fitness and risk of heart failure: A population-based follow-up study. *European Journal of Heart Failure*. 2014; 16:180-188.
  26. Mettaeur B, Zoll J, Sanchez H, et al. Oxidative capacity of skeletal muscle in heart failure patients versus sedentary or active control subjects. *Journal of American College of Cardiology*. 2001; 38(4):947-54.
  27. Aune D, Sen A, Norat T, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality. A systematic review and dose-response meta-analysis of prospective studies. *Circulation*. 2016;133(7):639-49.
  28. Málek F. Arterial hypertension and chronic heart failure. *Cor Et Vasa*. 2013;55(3): e259-e263.
  29. Tavazzi L. Heart rate as a therapeutic target in heart failure? *European Heart Journal Supplements*. 2003;5(G):15-18.

---

© 2019 Sane and Mandole; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*

*The peer review history for this paper can be accessed here:*  
<http://www.sdiarticle3.com/review-history/43550>